Cabozantinib
A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 86 patients (estimated)
- Sponsors
- Memorial Sloan Kettering Cancer Center
- Collaborators
- Exelixis
- Tags
- Tyrosine Kinase (TK) Inhibitor
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1396
- NCT Identifier
- NCT01639508
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.